Organon & Co. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number
Organon & Co. (OGN) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number of 3.95 million shares as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber · last filed 2026-07-31
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 3.95M shares.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 4.61M shares.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 5.32M shares.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 5.34M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number as first filed |
|---|---|---|
| 2026-06-30 | 3.95M shares 10-Q · filed 2026-07-31 | |
| 2026-03-31 | 4.61M shares 10-Q · filed 2026-05-04 | |
| 2025-12-31 | 5.32M shares 10-K · filed 2026-02-24 | |
| 2025-09-30 | 5.34M shares 10-Q · filed 2025-11-10 | |
| 2025-06-30 | 5.34M shares 10-Q · filed 2025-08-06 | |
| 2025-03-31 | 5.50M shares 10-Q · filed 2025-05-02 | |
| 2024-12-31 | 4.64M shares 10-K/A · filed 2025-11-10 | 4.64B shares 10-K · filed 2025-02-28 |
| 2024-09-30 | 4.66B shares 10-Q · filed 2024-11-01 | |
| 2024-06-30 | 4.31B shares 10-Q · filed 2024-08-07 | |
| 2024-03-31 | 3.84B shares 10-Q · filed 2024-05-03 | |
| 2023-12-31 | 3.31B shares 10-K · filed 2024-02-26 | |
| 2023-09-30 | 3.31B shares 10-Q · filed 2023-11-03 | |
| 2023-06-30 | 3.32B shares 10-Q · filed 2023-08-09 | |
| 2023-03-31 | 2.54B shares 10-Q · filed 2023-05-05 | |
| 2022-12-31 | 2.38B shares 10-K · filed 2023-02-27 | |
| 2022-09-30 | 2.43B shares 10-Q · filed 2022-11-04 | |
| 2022-06-30 | 2.43B shares 10-Q · filed 2022-08-05 | |
| 2022-03-31 | 1.44M shares 10-Q · filed 2022-05-06 | |
| 2021-12-31 | 1.45M shares 10-K · filed 2022-03-21 | |
| 2021-09-30 | 1.45M shares 10-Q · filed 2021-11-12 | |
| 2021-06-30 | 1.45M shares 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |